University of Gothenburg
Skoog is the leading authority on vascular dementia epidemiology, the role of vascular factors in AD and vascular cognitive impairment. The group focuses on the epidemiology of AD, with clinical diagnostic and etiologic approaches, and a strong Molecular Epidemiology focus related to use genetic and other biomarkers.
Gustafson, author of first reports on relationships between adiposity and AD, cerebrovascular disease, and brain atrophy. Epidemiologic studies in Gothenburg are unique due to the length of time populations have been followed, clinical dementia and cognitive assessments, somatic disorder ascertainment, and routine and detailed risk and protective factor measures. All participants engage in a one day clinical examination, and world-renowned Swedish registry data is used to track those lost to follow-up. The Blennow group adds a strong focus on the measurement and development of blood and cerebrospinal fluid biomarkers for AD and genetic analyses of APOE which are used in the epidemiologic studies. Epidemiologic studies will directly benefit from Prof. Blennow’s determination of CSF and basic science biomarkers.
SUNY-Downstate Medical Center
Blennow is head of the Clinical Neurochemistry Laboratory at Sahlgrenska University Hospital, Göteborg, Sweden. The laboratory has a long-standing experience in CSF analyses for brain disorders. The research group has a focus on CSF biomarkers for AD with a large experience in protein analyses, immunoassays and proteomics/mass spectrometry.
Blennow is beyond doubt the most productive specialist on AD CSF biomarkers and the leading authority. Very recently his breakthrough discovery of very early diagnosis of prodromal/MCI AD caused a shift in the way early AD diagnosis is seen.